Title |
Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial
|
---|---|
Published in |
BMC Urology, September 2013
|
DOI | 10.1186/1471-2490-13-45 |
Pubmed ID | |
Authors |
Vik Khullar, Javier Cambronero, Javier C Angulo, Marianne Wooning, Mary Beth Blauwet, Caroline Dorrepaal, Nancy E Martin |
Abstract |
Antimuscarinic agents are currently the predominant treatment option for the clinical management of the symptoms of overactive bladder (OAB). However, low rates of persistence with these agents highlight the need for novel, effective and better-tolerated oral pharmacological agents. Mirabegron is a β3-adrenoceptor agonist developed for the treatment of OAB, with a mechanism of action distinct from that of antimuscarinics. In a randomized, double-blind, placebo- and active-controlled Phase 3 trial conducted in Europe and Australia (NCT00689104), mirabegron 50 mg and 100 mg resulted in statistically significant reductions from baseline to final visit, compared with placebo, in the co-primary end points - mean number of incontinence episodes/24 h and mean number of micturitions/24 h. We conducted a post hoc, subgroup analysis of this study in order to evaluate the efficacy of mirabegron in treatment-naïve patients and patients who had discontinued prior antimuscarinic therapy because of insufficient efficacy or poor tolerability. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 1 | 2% |
Unknown | 53 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 9 | 17% |
Researcher | 7 | 13% |
Student > Master | 6 | 11% |
Student > Bachelor | 6 | 11% |
Student > Doctoral Student | 3 | 6% |
Other | 11 | 20% |
Unknown | 12 | 22% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 26 | 48% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 6% |
Biochemistry, Genetics and Molecular Biology | 2 | 4% |
Unspecified | 2 | 4% |
Nursing and Health Professions | 2 | 4% |
Other | 3 | 6% |
Unknown | 16 | 30% |